NASDAQ: PLURPluri Inc Stock
$5.01-0.24 (-4.57%)
Updated Apr 22, 2024
PLUR Price
$5.01
Fair Value Price
-$0.69
Market Cap
$25.98M
52 Week Low
$3.45
52 Week High
$8.56
P/E
-1.08x
P/B
5.91x
P/S
67.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$357.00k
Earnings
-$23.95M
Gross Margin
97.5%
Operating Margin
-6,242.02%
Profit Margin
-6,708.4%
Debt to Equity
7.94
Operating Cash Flow
-$18M
Beta
0.85
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PLUR Overview
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PLUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLUR ($5.01) is overvalued by 821.81% relative to our estimate of its Fair Value price of -$0.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLUR ($5.01) is not significantly undervalued (821.81%) relative to our estimate of its Fair Value price of -$0.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLUR due diligence checks available for Premium users.
Be the first to know about important PLUR news, forecast changes, insider trades & much more!
PLUR News
Valuation
PLUR fair value
Fair Value of PLUR stock based on Discounted Cash Flow (DCF)
Price
$5.01
Fair Value
-$0.69
Undervalued by
821.81%
PLUR ($5.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLUR ($5.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PLUR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.08x
Industry
16.21x
Market
41x
PLUR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.91x
Industry
5.82x
PLUR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLUR's financial health
Profit margin
Revenue
$105.0k
Net Income
-$4.9M
Profit Margin
-4,671.4%
PLUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLUR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$41.6M
Liabilities
$34.9M
Debt to equity
7.94
PLUR's short-term assets ($32.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLUR's short-term assets ($32.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLUR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PLUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
$3.9M
Financing
$0.0
PLUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PLUR vs Biotech Stocks
Pluri Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.